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ABSTRACT: Wntsignalinghasemergedasacentralregulatorofskeletalmodelingandremodeling.Loss-orgain-
of-function mutations in two Wnt co-receptors, Lrp5 and (more recently) Lrp6, have drawn attention to the
importanceoftheWntpathwayinbonebiology.ThisreviewsummarizesourcurrentunderstandingofhowtheWnt
pathway operates on bone and the implications this has for skeletal physiology and drug discovery. Over the past
9 yr, rapid advances have been made in our understanding of the cellular targets for Wnt signaling and of the
important regulatory molecules in this metabolic pathway. Both canonical and noncanonical signaling pathways
seem to be important for mediating the effects of Wnt in bone. A rapidly expanding catalog of genetically engi-
neeredmicehasbeenusedtoestablishtheimportanceofdownstreameffectormolecules(suchasb-catenin)inthe
Wnt pathway, as well as thecriticalrole ofendogenous inhibitorsof Wntsignaling (such as Dkk1 and sclerostin)in
bone metabolism. Indeed, regulation of sclerostin in osteocytes is emerging as an important ﬁnal pathway for
regulatingbone anabolism inresponse to diverse trophic stimuli, frommechnotransduction to theanabolicactions
ofPTH.Fromtheoutset,ithadbeenassumedthattheeffectsofWntsignalinginbonewerecausedbydirectactions
in osteoblast precursors, osteoblasts, and osteocytes. However, startling recent ﬁndings have challenged this view
and suggest that a key target, at least in mice, is the duodenal enterochromafﬁn cell. There, Wnt signaling trans-
duced by Lrp5 regulates serotonin synthesis, which acts in an endocrine fashion to regulate bone cell metabolism.
It will take time to reconcile this new information with the considerable body of information we already have
regarding the actions of Wnt in bone. The Wnt pathway has rapidly emerged as a therapeutic target for drug
discovery. Neutralizing antibodies and small-molecule inhibitors of endogenous Wnt inhibitors have shown early
promise as bone anabolic agents. However, given the central role of the Wnt pathway in regulating growth and
development in extraskeletal tissues, as well as our still rudimentary understanding of how this signaling cascade
actually affects bone metabolism, considerable work will be needed to ensure the safety of these new therapies.
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INTRODUCTION
W
HEN THE LOW-DENSITY lipoprotein–related receptor
5 and 6 (Lrp5 and Lrp6) genes were cloned in 1998
based on their homology with the low-density lipoprotein
receptor (LDLR),
(1–4) it would have been difﬁcult to an-
ticipate the key role that they play in skeletal development
and disease. Mutations in either LRP5 or LRP6, proteins
with which they directly interact, or their downstream
signaling targets have been associated with several bone-
related diseases, as well as with many types of cancer,
(5)
abnormalities of the eye,
(6) neurodegenerative disease,
(7)
congenital heart defects,
(8) and metabolic disorders.
(9) The
focus of this perspective will be to brieﬂy describe the
structure and functions of Lrp5/Lrp6 and their role in
skeletal development and remodeling, followed by a sum-
mary of areas of current research and future investigative
efforts in this exciting new area in bone biology.
STRUCTURE OF Lrp5 AND Lrp6
Lrp5andLrp6are71%homologousandformasubclassof
the LDLR family.
(10) They share a structure that contains a
large extracellular domain (ECD) making up >85% of the
;1600-amino-acid proteins. At the amino terminus of the
ECD, four b-propeller motifs alternate with four epidermal
growth factor (EGF)-like repeats to create binding sites for
most of the known extracellular ligands for Lrp5 and Lrp6.
Structural models suggest that each of these b-propeller
domains resembles the YWTD/EFG domain structure of
the LDLR, which has a six-bladed propeller structure where
each blade consists of ;43 amino acids. In a recent model of
t h eL r p 5s t r u c t u r e ,B h a te ta l .
(11) described the b-propeller
as ‘‘a disk with inward-sloping sides surrounding a central
open area.’’ Another way to visualize this would be to
consider this as a funnel-like structure.
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of ;38 amino acids highly homologous to lipoprotein lig-
and-binding domains in the LDLR. The precise function of
these repeats is not entirely understood; however, there is
much circumstantial evidence to support an important
physiological role. For example, there is evidence that Wnt
ligands are presented to these receptors in the form of a
lipid-rich complex.
(12) In addition, Lrp5 has been shown to
mediate the binding of apolipoprotein particles to cells,
(4)
and both Lrp5-deﬁcient mice
(13,14) and humans with mu-
tations in LRP6
(15) have elevated levels of plasma LDL
and triglycerides, suggesting that these molecules may play
direct roles in regulating lipid metabolism.
TheECDisanchoredtotheplasmamembranethrougha
22-amino-acidsingle-passtransmembranedomain,whichis
followedbyarelativelyshort(207aminoacids)cytoplasmic
domain.Themostobviousmotifsinthecytoplasmicdomain
are a series of highly conserved PPPS/TP motifs. The serine
or threonine residues in these proline-rich regions are
phosphorylated on activation by Wnts or other ligands such
as PTH (see below). These phospho-serine or phospho-
threonine residues serve as binding sites for the axin pro-
teins, resulting in stabilization of b-catenin.
(10) In addition,
Wnt-induced activation of Lrp5 or Lrp6 can directly acti-
vate the mammalian target of rapamycin (mTOR) path-
way,
(16) raising the possibility that some phenotypes asso-
ciated with activation of this pathway could be ameliorated
through treatment with rapamycin.
The expression of an alternatively spliced form of LRP5
may also play a role in regulating the actions of this co-
receptor. One of the ﬁrst reports on Lrp5 (originally re-
ferred to as Lrp7/Lr3) described an alternatively sized
mRNA expressed during embryogenesis and in the tes-
tis.
(17) More recently, Pospisil et al.
(18) also reported evi-
dence for splicing of Lrp5. The alternatively spliced form of
Lrp5directs the synthesisof a protein that lacks the thirdb-
propeller domain and that is not subject to regulation by
the Dkk1 protein. An alternatively spliced form of Lrp5
has also been identiﬁed in parathyroid tumors.
(19) Given
the structural complexity of the Lrp5 protein, it is tempting to
speculate that these alternative transcripts have important
roles during development and perhaps in the pathogenesis of
some neoplasms, possibilities that merit more study.
REGULATION OF Lrp5 AND Lrp6 ACTIVITY
The most studied functions of Lrp5 and Lrp6 are their
roles as co-receptors for the frizzled family of Wnt recep-
tors. Their Wnt ligands are a family of proteins encoded by
19 different genes in vertebrates. The Wnt signaling path-
way is one of the most highly conserved signaling cascades
identiﬁed with functional activity in organisms including,
but not limited to, Hydra, planaria, Drosophila, Caeno-
rhabditis elegans, and all vertebrate species examined.
(20)
Wnts are a family of cysteine-rich secreted glycopro-
teins
(20) that induce signals through several intracellular
cascades. In the most studied (‘‘canonical’’) pathway, Wnt
binds to a receptor complex that includes both a member
of the frizzled family of seven-transmembrane receptors
(encoded by 10 genes in humans) and either Lrp5 or
Lrp6.
(10) This results in phosphorylation of the intracellular
cytoplasmic tail of Lrp5 or Lrp6, creating a binding site for
the Axin protein. Normally, Axin is part of an intracellular
protein complex that facilitates the phosphorylation of
b-catenin by glycogen synthase kinase 3 (GSK3), thereby
targeting b-catenin for ubiquitin-dependent proteolytic
degradation. In the presence of Wnt ligands, GSK3 kinase
activity is inhibited resulting in increased levels of cyto-
plasmic and nuclear b-catenin.
Activation of the pathway can also be caused by inacti-
vating mutations in genes encoding proteins needed for
normal targeting of b-catenin for degradation or activating
mutations in the b-catenin gene itself.
(5) These increased
levels of b-catenin form complexes with members of the
LEF/TCF family of DNA-binding proteins and activate
promoters of numerous target genes.
(21) Recently, two
novel signaling molecules were linked to regulation of ca-
nonical Wnt signaling. Activation of canonical Wnt sig-
naling through Lrp6 requires phosphorylation of Lrp6 on
serine residues within the cytoplasmic domain. Pan
et al.
(22) have reported that Wnt3a induces activation of
two lipid kinases that generate the signaling molecule
phosphoinositol 4,5-bisphosphate, which in turn regulates
phosphorylation of Ser
1490 on Lrp6. Wu et al.
(23) have re-
ported that the small GTPase Rac1 is needed for phos-
phorylation of b-catenin on serines 191 and 605 through
JNK2 (c-jun N-terminal protein kinase 2), a step required
for nuclear localization of b-catenin.
In addition to canonical signaling, several Wnt proteins
activate noncanonical pathways that do not target b-cat-
enin.
(24) Different signaling molecules are reportedly engaged
by different Wnts in bone cells through the noncanonical
pathway. Wnt5a has been reported to activate a histone lysine
methyltransferase, STEDB1, through a Nemo-like kinase
that is downstream from calcium/calmodulin-dependent ki-
nase II. Activation of SETDB1 inhibits peroxisome pro-
liferator-activated receptor (PPAR)g signaling and stimu-
lates osteoblastogenesis.
(25) Wnt3a and Wnt7a have been
reported to activate a signaling complex that includes the G-
protein Gaq/11 and targets the novel protein kinase C family
member, PKCd, which drives osteoblast differentiation.
(26)
The signaling functions of Lrp5 and Lrp6 are tightly
regulated by a large number of extracellular proteins in-
cluding members of the Dickkopf (Dkk) family. Dkks are
encoded by a four-member gene family in vertebrates, of
which three members (Dkk1, 2, and 4) are reported to
interact with Lrp5 and/or Lrp6.
(27) The proteins are pri-
marily composed of two cysteine-rich domains that are
homologous to colipase folds. They bind to regions within
the b-propeller motifs of Lrp5 and Lrp6 and inhibit the
ability of Wnt ligands to bind and activate downstream
signaling. Dkk-based inhibition may occur by directly
blocking the ability of Wnt ligands to bind Lrp5 and/or
Lrp6, or it may decrease the availability of Lrp5 and Lrp6
at the plasma membrane surface.
(27) This latter mechanism
is related to the ability of Dkks to simultaneously bind Lrps
and members of the Kremen protein family. The formation
of heterotrimeric or higher order complexes containing
Dkks, Lrps, and Kremens leads to the internalization of the
complex and a decrease in the levels of Lrps at the cell
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bers of the R-spondin family, which may bind directly to
the Lrps or to Kremen proteins, inhibiting their ability to
interact with Dkks.
(28) However, the role of Kremen is still
being debated,
(29–31) because some studies have suggested that
Kremens are not required to mediate the actions of Dkks.
Several other proteins such as sclerostin, R-spondins, and
members of the cysteine-knot-type proteins (including con-
nective tissue growth factor and Wise) bind and regulate the
activity of Lrp5 and Lrp6.
(32) Sclerostin is of particular in-
terest because the gene encoding this protein was originally
identiﬁed as being mutated in sclerostosis,
(33) a human dis-
ease characterized by high bone mass and an unusually
square jaw,
(34) the latter reminiscent of the jaw phenotype
observed in some patients bearing the Lrp5G171V gain-of-
function mutation (see below). Cranial nerve root entrap-
ment leading to loss of hearing and vision, as well as tri-
geminal neuralgia, can also occur in this disease. The ex-
pression of sclerostin is restricted to osteocytes, making it an
appealing therapeutic target for drug therapy of low bone
mass (see below). As an example, overexpression of a con-
stitutively active PTH receptor in osteocytes results in in-
hibition of sclerostin and a striking increase in bone mass,
consistent with the hypothesis that some of the anabolic
actions of PTH may be mediated by suppressing sclerostin
expression.
(35) Finally, Lrp-based signaling may also be
controlled by regulating the transit of Lrp5 and Lrp6 to the
cell surface. This is based on work showing that the Meso-
derm speciﬁcation (Mesd) protein acts as a molecular cha-
perone and is required for such transit.
(36)
Wnt RECEPTOR COMPLEX AND ITS
ASSOCIATION WITH SKELETAL
DEVELOPMENT AND REMODELING
Osteoporosis pseudoglioma (OPPG) is a rare syndrome
associated with a dramatic reduction in skeletal mass, evi-
dent in infancy, that results in devastating fragility fractures.
Limited histologic data indicate that bone formation rates
are reduced in this disease. OPPG is accompanied by pro-
gressive blindness also beginning in childhood. In 2001,
inactivating mutations in LRP5 were identiﬁed as the
causative genetic basis for OPPG.
(37) Analysis showed that
Lrp5was expressedbycellsinthe osteoblastlineage,but not
by osteoclasts, and much of the subsequent work has fo-
cused on this cell type as the central mediator of its actions
on bone. However, as discussed below, the importance of
Lrp5-mediated signaling within osteoblasts will have to be
reconsidered in light of new evidence.
(38) The progressive
blindness in these patients is related to a failure of the hy-
aloid vessels of the lens to regress after birth.
(39) Interest-
ingly, other diseases associated with abnormal angiogenesis
or vascularization of the eye are also associated with mu-
tations in Lrp5 or Lrp6 or in proteins that interact with the
two receptors, including familial exudative vitreoretinopa-
thy,
(40–42) Norrie disease,
(43) and macular degeneration.
(44)
Additional support for the role of LRP5 in bone growth
wasprovidedwhentwogroupsindependentlyreportedthat
a point mutation in LRP5 (G171V) was present in affected
individuals of families showing an autosomally dominant
high bone mass trait.
(45,46) These two genetically indepen-
dent families have BMD ;5 SD above that of unaffected
family members and the general population. One of these
original two families had a notable skeletal phenotype with
straightening of the angle of the jaw, torus palatines, and
torus mandibularis. Torus palatinus and torus mandibularis
have subsequently been found to be associated with higher
bone mass in postmenopausal women.
(47) Individuals with
the LRP5G171V mutations have normal lifespans, rarely
fracture, and have little skeletal morbidity, although one of
us has cared for a patient who developed thoracic com-
pression myelopathy caused by bony overgrowth of his
vertebral body (K Insogna, unpublished data).
Theglycinenormallyatposition171intheLrp5proteinlies
within the fourth blade of the ﬁrst six-bladed b-propeller. The
G171V mutation does not directly increase signaling activity;
instead, it inhibits the ability of Dkk1, Sost, and potentially
other proteins to bind to Lrp5 and inhibit Wnt signaling. In
addition, it may interfere with Mesd binding and the transit of
Lrp5 to the cell surface, facilitating increased autocrine sig-
naling within the endoplasmic reticulum. Subsequently, at
least six other mutations in human Lrp5 have been identiﬁed
and correlated with changes in bone mass.
(48)
Mutations in LRP6 have also been linked to changes in
bone mass in humans. Members of a family in which a
putative partial loss-of-function mutation in LRP6 was
identiﬁed were predisposed to early cardiovascular-related
death associated with dramatically elevated levels of
plasma LDL and triglycerides, hypertension, diabetes, and
osteoporosis.
(15) In addition, several mutant mouse models
with induced or spontaneous mutations in Lrp6 have been
identiﬁed and characterized, with some of these mice re-
ported to have alterations in bone development.
(49–52)
Given the dramatic skeletal phenotypes of patients
bearing mutations in LRP5 and LRP6, there has been
considerable interest in determining whether polymor-
phisms in LRP5 or LRP6 contribute to heritability of bone
mass. Several small studies have variably reported associ-
ations (or no associations) of LRP5 polymorphisms with
bone mass at selected skeletal sites in adults and children.
However, two large, recent, genome-wide association
studies have ﬁrmly established an association between al-
lelic variants in LRP5 and both bone mass and fracture
risk.
(53,54) Both studies reported a signiﬁcant association of
the SNP rs3736228 (Ala1330Val) with reduced bone mass
and an increased risk of fracture.
InadditiontotheroleofLrp5/6ininheritedsyndromesof
high and low bone mass, evidence is emerging for a role for
these molecules in acquired skeletal diseases. One striking
exampleismyelomabonedisease,whichischaracterizedby
increased bone resorption but suppressed bone formation.
Tian et al.
(55) have reported that the inhibitor of Lrp5 sig-
naling, Dkk1, is secreted by myeloma cells and have pro-
vided evidence to indicate that this is the mediator of
myeloma-induced suppression of osteoblast activity.
As described below, animal models have provided consid-
erableinsightintothemechanismsbywhichgainoffunctionin
Lrp5/Lrp6 signaling results in a high bone mass phenotype.
However, in vivo studies in humans examining the mecha-
nismsofactionofLrp5/6arelargelylacking.Qiuetal.
(56) have
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bearing the Lrp5G171V mutation, although formal static and
dynamic histomorphometry was not reported.
MOUSE MODELS WITH TARGETED
MUTATIONS IN Lrp5, Lrp6, AND OTHER
COMPONENTS OF THE Wnt
SIGNALING PATHWAY
Lrp5
–/– mice have lower-than-normal BMD and a per-
sistence of the embryonic eye vasculature, accurately mod-
eling human OPPG.
(57) Detailed studies on these mice
showed reductions in osteoblast proliferation and function,
and they also suggested defects at multiple stages of differ-
entiation. This is consistent with reports showing roles for
Lrp5in bothterminaldifferentiationandintheregulationof
proliferation of pre- and early osteoblasts. A mouse strain
designed to model the high bone mass phenotypes in hu-
mans carrying the G171V mutation has been developed
using a rat type I collagen promoter to preferentially drive
expression of a Lrp5G171V cDNA in osteoblasts. The re-
sulting mice show increased bone mass, decreased osteo-
blast apoptosis, and increased bone strength.
(58) Whereas
this work clearly showed that this point mutation could in-
crease bone mass when speciﬁcally expressed in osteoblasts,
its tissue-speciﬁc expression did not allow a thorough eval-
uation ofthe potential sideeffects ofexpressingthe mutated
protein under its endogenous promoter. Despite carrying a
mutation capable of increasing the levels of canonical Wnt
signaling, human patients carrying this mutated version of
LRP5 have not been reported to have increased suscepti-
bility totumorigenesis. However, there are a relativelysmall
number of these patients. Given the current interest in de-
veloping agents that pharmacologically mimic such muta-
tions that build bone mass, a detailed study of all tissues in
micecarryingthismutationintheendogenouschromosomal
location would contribute valuable insights.
Mice carrying a heterozygous null mutation in Lrp6 have
low bone mass.
(50) Further support for a key role for Lrp6
in regulating bone development has been provided by the
analysis of bone defects in mice homozygous for a hypo-
morphicalleleofLrp6(ringelschwanz)ca us e dbyanR8 86 W
point mutation.
(51) Mice homozygous for this allele survive
to adulthood but show evidence of delayed ossiﬁcation and
osteoporosis. Homozygosity for a null allele of Lrp6 causes
neonataldeathassociatedwithalossofdistallimbstructures
a n dt r u n c a t i o no ft h ea x i a ls k e l e t o n .
(59) Further support for
the importance of Lrp6 in bone development comes from
observations that mutations in both Lrp5 and Lrp6 cause
synergisticdefectsinlimbdevelopmentandbonemass.
(50,60)
As mentioned, Lrp5/6 serve as ‘‘co-receptors’’ for the
Frizzled family of Wnt receptors. Whereas mutations in
Frizzled genes have not been associated with changes in
human bone disease, mice carrying genetic deletion of
Frizzled-9 have a low bone mass phenotype.
(61)
Several laboratories have examined the roles of the down-
stream components of the Wnt signaling pathway in skeletal
metabolism. Speciﬁcally, the b-catenin and Apc genes have
been conditionally deleted at different stages of osteoblast
differentiation. Deletion of b-catenin in differentiated oste-
oblasts (either through Osteocalcin-cre
(62) or Collagen1a1-
cre
(63)) caused severe osteopenia associated with increased
osteoclastogenesis, which correlated with altered expression
of RANKL and osteoprotegerin (OPG). In contrast, activa-
tion of b-catenin in osteoblasts (either through induction of
an oncogenic version of b-catenin
(63) or by inactivation of the
Apc tumor suppressor gene
(62)) leads to dramatic increases in
osteoid deposition and severely impaired osteoclastogenesis.
Interestingly, these effects on osteoclasts are not seen in hu-
mans or mice lacking LRP5.
(37,57) Mice with deletions of
b-catenin in mesenchymal condensations have also been
created by either Dermo1-cre or Prx1-cre–mediated gene
deletion. In this context, loss of b-catenin leads to an arrest of
osteoblastdifferentiationandenhancedchondrogenesis,
(64–66)
implying that b-catenin is needed for the initial speciﬁca-
tion of osteoblasts.
Complementing the overexpression and gene deletion
studies in which agonists of the Wnt signaling cascade have
been manipulated, are studies in which endogenous inhibi-
tors of Wnt signaling have been altered. Consistent with the
notionthatDkk1playsanimportantroleinsuppressingWnt
signaling, haploinsufﬁciency for Dkk1 results in a high bone
massphenotypeinmice.
(67)Surprisingly,theDkk2 knockout
mouse does notevidencealterations inbone massbut rather
has a mineralization defect, suggesting an unexpected con-
tribution of this molecule to osteoblasts differentiation.
(68)
Targeted overexpression of another inhibitor of Wnt sig-
naling, secreted frizzled related protein-4 (SFRP4) in oste-
oblasts,results ina lowbone massphenotype.
(69)Transgenic
overexpression of the Wnt antagonist Kremen 2 in osteo-
blasts also severely impairs bone formation.
(70) Finally, de-
letion of the secreted Wnt signaling inhibitor, Sfrp1, leads to
the development of high bone mass in older mice.
(71)
In addition, emerging evidence suggestsan important role
for Lrp5 in modulating the response to mechanical strain in
vivo. Mechanotransduction is thought to be mediated prin-
cipally by osteocytes, and work of Sawakami et al.
(72) has
shown that the anabolic response to mechanical strain in
normal mice was completely lost in mice in which the Lrp5
gene had been deleted. The link between mechano-
transduction and Wnt signaling may in part be dependent
on sclerostin, the endogenous Wnt-signaling inhibitor,
which is expressed in osteocytes. Osteocyte expression of
sclerostin is suppressed by mechanical strain.
(73)
As noted above, studies examining how Lrp5/6 signaling
affectsbonemetabolismhavebeenentirelypredicatedonthe
assumption that altered Wnt signaling in bone cells is the
basis for the observed phenotypes. However, Lrp5 is widely
expressed,
(3) and the Wnt proteins have wide tissue distri-
butions as well. Recently, Yadov et al.
(38) reported dramatic
ﬁndings that challenge the ‘‘osteoblast-centric’’ model of
Lrp5 action. As noted, deletion of Lrp5 in mice leads to a
low bone mass phenotype. Yadav et al. found that targeted
deletion of Lrp5 in the duodenal enterochromafﬁn cells of
mice results in high circulating levels of serotonin caused by
upregulation of the rate-limiting enzyme for serotonin syn-
thesis,tryptophanhydroxylase(Tph1).Dietaryrestrictionof
tryptophan resulted in reduced circulating levels of seroto-
nin in Lrp5-deﬁcient mice and normalized the suppressed
bone formation parameters in these animals, suggesting that
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for this effect. Consistent with this idea, restricted expres-
sion of Lrp5G171V in the duodenum resulted in a high bone
mass phenotype. These investigators went on to show that
the serotonin receptor Htr1b mediates the actions of sero-
tonin in osteoblasts, because selective deletion of this re-
ceptor in osteoblasts resulted in a high bone mass pheno-
type. Interestingly, using a genetic approach they provide
evidence that the mechanism by which Lrp5 regulates Tph1
activity in the duodenum is not through a b-catenin path-
way. These data suggest that a new endocrine loop, from the
gut to bone in which serotonin is the effector hormone, may
play a central and hitherto unappreciated role on bone
metabolism. They also call into question the role of Lrp5 in
bone cells. Recent clinical evidence has suggested an im-
portant role for the serotonergic system in regulating bone
mass, with reports of reduced bone mass and an increased
risk of fracture in patients taking selective serotonin reup-
take inhibitors (SSRIs).
(74–76) SSRIs are not thought to alter
serum serotonin levels, so the relationship of this clinical
observation to the ﬁndings of Yadav et al. remains unclear.
THERAPEUTIC MANIPULATION OF THE
Wnt Lrp5/6 SIGNALING CASCADE
Because gain-of-function mutations in LRP5 result in a
high bone mass phenotype in which the quality of the bone
is good and fracture risk is very low, there is considerable
interest in attempting to therapeutically manipulate Wnt
signaling in patients with low bone mass. Initial efforts
have focused on suppressing endogenous inhibitors of the
Wnt signaling system.
Sclerostin has emerged as an attractive therapeutic target
because its expression is restricted to osteocytes. A neutral-
izing antibody to sclerostin has shown promise in initial pre-
clinical and early clinical trials.
(77,78) Experimental animals
showed an increase in bone formation rates and bone mass
during treatment with this antibody, and postmenopausal
women treated with a neutralizing antibody showed an in-
crease in markers of bone formation. A neutralizing anti-
body to Dkk1 hasalsoshown promiseinapreclinical trial.
(79)
A small-molecule inhibitor of SFRP1 has been shown to
stimulate bone formation in mice.
(80) Thus, drugs targeting
theseendogenous inhibitors of Wnt signaling may be the ﬁrst
useful therapies to emerge from our new appreciation of the
importance of this signaling cascade in bone.
BecausePTHistheonlyavailableanabolicagentforbone,
the relationship between its use for that purpose and Wnt-
mediated bone anabolism has been an area of considerable
investigativeinterest.Anumberofstudiessuggestthatthese
two signaling pathways do indeed overlap. Recent examples
includepreliminaryreportsthatPTHisabletostimulateab-
catenin–responsive reporter construct in vitro and that PTH
induces interaction of the PTH receptor, PTHR1, with
LRP6.
(81) The formation of a ternary complex of ligand,
receptor and Lrp6, is associated with phosphorylation of
Lrp6.Intermsofbuildingandmaintainingbone,therelative
contributions of PTH from activating Lrp6 and from
downregulating the expression of sclerostin
(35,82) will un-
doubtedly be the subject of intense future study.
FIG. 1. The canonical Wnt (Wnt/b-catenin) signaling pathway
(adapted from Ref. 84). (A) In the absence of an upstream in-
hibitory signal induced by Wnt ligands, the constitutively active
serine/threonine protein kinase, glycogen synthase kinase 3
(GSK3a or GSK3b), phosphorylates b-catenin on conserved ser-
ine or threonine residues near its amino terminus. This process
depends on the formation of a large, multiprotein complex that
includes the Axin protein and the product of the Adenomatous
polyposis coli (APC) gene. Phosphorylation of b-catenin targets it
for degradation through a ubiquitin-dependent proteolytic path-
way. In addition, GSK3 activity also controls the activity of the
tuberoussclerosiscomplex,consisting ofthe tuberinandharmartin
proteins (encoded by the TSC1 and TSC2 genes, respectively).
GSK3-mediated phosphorylation of TSC1 inhibits this complex,
leading to downregulation of the small GTPase, Rheb. This, in
turn, results in decreased activity of the mTOR complex (which is
activated by Rheb-GTP). Because mTOR normally activates
proteins that increase the cellular capacity for translational activ-
ity, the net effect of GSK3 activity in the context of canonical Wnt
signaling is to downregulate both transcriptional (through b-cat-
enin target genes) and translational (through mTOR regulation)
activity. (B) In the presence of an upstream Wnt ligand, GSK3
activity is inhibited, leading to increased cytoplasmic levels of b-
catenin, which enters the nucleus and activate transcription of
target genes. In addition, inhibition of GSK3 also leads to activa-
tion of the mTOR pathway. A parallel pathway leads to the JNK2-
dependent phosphorylation of b-catenin, which facilitates nuclear
localization. Thus, the net result of activation of canonical Wnt
signaling is to coordinately increase both transcriptional (through
increased activation of b-catenin target genes) and translational
(through activation of mTOR) activation within cells. Activation
of the pathway is normally constrained by the expression of pro-
teins such as members of the Dickkopf family and sclerostin, which
selectively bind to either Lrp5 or Lrp6, thereby blocking the ability
of Wnt ligands to interact with these receptors. In addition, pro-
teins of the secreted frizzled related protein (Sfrp) family can di-
rectly bind to Wnt ligands, offering another way to inhibit
activation of the pathway.
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The past 7 yr has seen an explosion in our understanding
of the mechanisms underlying the role of Wnt signaling in
the regulation of bone mass. The recent work of Yadav
et al. that indicates a central role for circulating serotonin
in regulating bone formation suggests that inhibiting the
actions of serotonin in bone or inhibiting its duodenal
synthesis may be new therapeutic targets for treating low
bone massconditions. Theseobservations will undoubtedly
stimulate a ﬂurry of activity directed at whether and how
the effects of serotonin and the documented role of Wnt/b-
catenin signaling within osteoblasts interact to control
bone development and homeostasis.
Finally, Lee et al.
(83) have also reported that the skeletal
system can play a direct role in regulating metabolism
through the actions of osteocalcin on pancreatic islets.
Coupled with reports that mutations in Lrp5 or Lrp6 in
humans and in mice impair the ability to normally regulate
serum levels of lipoproteins and glucose,
(13–15) it is tempt-
ing to speculate that there might be some connection be-
tween the role of Lrp5 and Lrp6 in regulating skeletal
development and the role of the skeleton as an endocrine
organ. In any case, it is likely that the role of Wnt signaling
in regulating the skeleton will be a large focus of ongoing
research efforts and that major surprises are in store as we
continue to explore this complex network.
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